Azenta (NASDAQ:AZTA) executives showcased their strategic turnaround during a presentation at the Raymond James Institutional Investor Conference, highlighting key initiatives aimed at enhancing operational efficiency and revenue growth. CEO John Marotta, who took the helm in September 2024, emphasized a renewed focus on portfolio management, operational improvements, and reallocating resources towards growth investments.
Marotta detailed Azenta’s significant market presence, noting its established relationships with top pharmaceutical and biotechnology firms. The company is integrated into the operations of over 20 leading pharma and biotech companies globally, supported by a robust infrastructure that includes more than 150 stores and thousands of instruments. This extensive footprint is expected to bolster market share and drive consumables growth, as the company serves approximately 14,000 customers worldwide.
### Business Segments and Operational Changes
Azenta operates primarily in two segments: sample management and multiomics. Marotta explained that the organization is investing in a digital ecosystem that enhances customer experience, allowing for remote management of samples. He acknowledged the complexities faced by the company, including the management of 60 million samples globally and the support of over 1 billion samples through customer sites and biorepositories.
Marotta indicated that Azenta’s trajectory had become “confused” due to years of acquisitions and centralization. To address this, he has initiated a series of operational simplifications. For instance, the company is divesting from B Medical, which Marotta identified as incompatible with the current portfolio. The divestiture is expected to close by the end of this month.
In addition, Azenta is restructuring its workforce, reducing approximately 300–350 corporate positions, with an additional 40 roles cut from the Sample Management Solutions (SMS) business. These changes are part of a broader strategy to cut general and administrative costs while reallocating funds to research and development, as well as sales and marketing efforts.
### Strategic Goals and Performance Tracking
To measure progress, the company has implemented monthly business reviews and established standardized key performance indicators (KPIs). These KPIs encompass customer satisfaction metrics such as quality and on-time delivery, as well as financial indicators like top-line growth and operating margin expansion.
In a conversation with Raymond James analyst Andrew Cooper, Marotta provided insights into the salesforce repositioning efforts across regions. He reported that Europe is approximately “eight to nine innings” into its commercial transformation and showing positive results. Conversely, North America is still catching up, with the SMS automated solutions team estimated at “seven to eight innings” of progress.
Marotta noted the need for broader changes within the Sample Repository Services (SRS) division, which had been adversely affected by pandemic-related disruptions. The organization has appointed a new leader and implemented changes over the last few months to align personnel with customer needs.
### Continuous Improvement Initiatives
Marotta, alongside Chief Financial Officer Lawrence Lin, discussed Azenta’s approach to continuous improvement, labeled as “ABS.” This method aims to enhance operating leverage, gross margin, and cash conversion through targeted initiatives that drive substantial improvements. One notable success in the GENEWIZ business saw customer delivery times slashed from 25 days to just nine hours following a focused week of restructuring efforts.
The company has also seen a significant reduction in customer complaints across stores, with complaints dropping by 55%. Furthermore, on-time delivery rates for consumables and instruments have improved from approximately 15% to 65%, with a target of reaching 95% by year’s end.
On the financial side, Marotta outlined plans for capital deployment, revealing that Azenta holds approximately $550 million in cash. The company intends to utilize this capital for gross margin enhancements, productivity improvements, strategic growth investments, potential mergers and acquisitions, and stock buybacks.
### Conclusion
Azenta, formerly the Life Sciences division of Brooks Automation, is strategically positioned to leverage its technological capabilities in sample management and genomic services. With a commitment to operational excellence and a clear focus on growth, the company is poised to navigate the challenges of the evolving life sciences landscape. As Marotta and his team implement their comprehensive turnaround strategy, all eyes will be on their progress in redefining Azenta’s market presence and operational efficiency.
